51% of infection preventionists cite lack of technology as biggest barrier

Over half of infection preventionists (IPs) reported a lack of technology as the main barrier in preventing healthcare-associated infections (HAI), according to a survey commissioned by 3M.

Preventing HAI is the main responsibility of IPs, but barriers in system optimization hold back the potential of prevention systems and put patients at risk. In the Human Factors and the Future of Infection Prevention survey, which included the responses from 650 American IPs and clinicians, researchers provided insight into barriers and perspectives on current IP systems.

Findings included:

  • 51% of IPs cited a lack of new technology and processes as the main barrier in preventing HAI, followed by insufficient support from senior leadership.
  • 50 percent believe there is poor compliance with infection prevention protocols.
  • One-third of clinicians surveyed believed infections could be avoided when providing healthcare.

“At 3M, we are on a mission to partner with clinicians to take on preventable infections,” said Pat Parks, MD, PhD, Medical Director, 3M Medical Solutions Division. “We wanted to gain a better understanding of beliefs and perceptions clinicians hold about the current reality and future potential of infection prevention. Armed with these insights, we’re convening with critical stakeholders to support clinicians in their fight against HAI.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.